Late detection is the primary cause of poor survival rates from cancer. Nanotechnology-enabled assays can detect early markers of cancer with much higher sensitivity than current detection methods. Existing assays use fluorescent probes with organic fluorophores or quantum dots, both of which have limitations. Organic fluorophores have limited brightness and photostability, reducing sensitivity and effective signal quantitation. Quantum dots exhibit toxicity and irregular blinking as well as broad emission spectra which reduces the level of multiplexing possible. We will develop a new class of ultrabright and ultrastable fluorescence probes, Surface Enhanced Fluorescence (SEF) Nanotags, to improve the sensitivity of fluorescence-based cancer detection. Nanoengineering of the SEF-nanotags to place fluorophores near the surface of plasmonic nanoparticles increases the light emission by up to a factor of 100X and significantly increases probe photostability. SEF probes will be functionalized with antibodies engineered to target cancer markers. The SEF nanotags will interrogate an analyte-containing solution and be detected on a microarray of complementary chemotropes. The brightness, photostability, and detection sensitivity of the SEF-nanotags will be compared to existing probes. These ultrabright and ultrastable SEF nanotags are easily adapted to existing fluorescence-based cancer diagnostics with improved sensitivity.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201100065C-0-0-1
Application #
8341466
Study Section
Project Start
2011-09-15
Project End
2012-06-14
Budget Start
Budget End
Support Year
Fiscal Year
2011
Total Cost
$200,000
Indirect Cost
Name
Nanocomposix, Inc.
Department
Type
DUNS #
159070825
City
San Diego
State
CA
Country
United States
Zip Code
92111